Cargando…

Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer

We conducted a feasibility study to examine whether small numbers of cancer cells could be utilised for analysis of the EGFR gene status using the loop-hybrid mobility shift assay, which is a modified heteroduplex technique. Cytology specimens obtained by transbronchial abrasion were successfully us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oshita, F, Matsukuma, S, Yoshihara, M, Sakuma, Y, Ohgane, N, Kameda, Y, Saito, H, Yamada, K, Tsuchiya, E, Miyagi, Y
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360725/ https://www.ncbi.nlm.nih.gov/pubmed/17047654 http://dx.doi.org/10.1038/sj.bjc.6603396

Ejemplares similares

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers
por: Savic, S, et al.
Publicado: (2008)

EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib
por: Kimura, H, et al.
Publicado: (2006)

Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells
por: Yokota, N, et al.
Publicado: (2009)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer
por: Nishii, Teppei, et al.
Publicado: (2014)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Can (18)F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis
por: Du, Bulin, et al.
Publicado: (2021)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

“Whirl Sign” of Primary Small Bowel Volvulus
por: Tamura, Jiro, et al.
Publicado: (2014)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer
por: Shimizu, K, et al.
Publicado: (2014)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Comparison of small biopsy and cytology specimens: Subtyping of pulmonary adenocarcinoma
por: Ma, Cao, et al.
Publicado: (2023)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway
por: Maseki, S, et al.
Publicado: (2012)

Metadherin regulates proliferation and metastasis via actin cytoskeletal remodelling in non-small cell lung cancer
por: Yao, Y, et al.
Publicado: (2014)

Detection of Merkel cell polyomavirus with a tumour-specific signature in non-small cell lung cancer
por: Hashida, Y, et al.
Publicado: (2013)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis
por: Tsuta, K, et al.
Publicado: (2014)

Concurrent infiltration by CD8(+) T cells and CD4(+) T cells is a favourable prognostic factor in non-small-cell lung carcinoma
por: Hiraoka, K, et al.
Publicado: (2006)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
por: Liu, Kejun, et al.
Publicado: (2020)

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
por: Kobayashi, M, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery
por: Renaud, Stéphane, et al.
Publicado: (2016)

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
por: Caputo, Alessandro, et al.
Publicado: (2021)

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients
por: Qiao, G-B, et al.
Publicado: (2005)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer
por: Nonomura, N, et al.
Publicado: (2007)

The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients
por: Mavridis, K, et al.
Publicado: (2015)

FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer
por: Cimino, Y, et al.
Publicado: (2012)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients
por: Nishio, M, et al.
Publicado: (2005)

Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78
por: Martin, S, et al.
Publicado: (2013)

The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
por: Nardone, Valerio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_clb2n0qlc3lhi4tcfcvpn6susb